Additionally, the delayed gastric emptying caused by GLP-1 medications may affect the absorption of some oral medicines, so follow product-specific guidance and consult your healthcare provider about potential interactions
glucagon activation increases energy expenditure and fat oxidation
The ADA standard for the treatment of diabetes updated in 2020 indicated that patients with T2DM diagnosed with CVD or those with CVD risk factors can use GLP-1RAs and SGLT2 inhibitors with evidence of cardiovascular benefits to reduce cardiovascular risk, regardless of HbA1c levels or individualized HbA1c control objectives [189]
Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
Essentially, GLP-1 medications work by suppressing appetite
The semaglutide dose that has been approved by FDA for weight loss usually ranges from 0.25 mg weekly (a typical starting dose) up to 2.4 mg, though it may shift according to your provider and experience with the medication
